These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10435495)

  • 1. Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease.
    Joost O; Taylor CA; Thomas CA; Cupples LA; Saint-Hilaire MH; Feldman RG; Baldwin CT; Myers RH
    Mov Disord; 1999 Jul; 14(4):590-5. PubMed ID: 10435495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease, CYP2D6 polymorphism, and age.
    Payami H; Lee N; Zareparsi S; Gonzales McNeal M; Camicioli R; Bird TD; Sexton G; Gancher S; Kaye J; Calhoun D; Swanson PD; Nutt J
    Neurology; 2001 May; 56(10):1363-70. PubMed ID: 11376189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 polymorphism and Parkinson's disease susceptibility.
    Sabbagh N; Brice A; Marez D; Dürr A; Legrand M; Lo Guidice JM; Destée A; Agid Y; Broly F
    Mov Disord; 1999 Mar; 14(2):230-6. PubMed ID: 10091614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson's disease].
    Durić G; Svetel M; Nikolaevic SI; Dragadević N; Gavrilović J; Kostić VS
    Vojnosanit Pregl; 2007 Jan; 64(1):25-30. PubMed ID: 17304721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease.
    Elbaz A; Levecque C; Clavel J; Vidal JS; Richard F; Amouyel P; Alpérovitch A; Chartier-Harlin MC; Tzourio C
    Ann Neurol; 2004 Mar; 55(3):430-4. PubMed ID: 14991823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism.
    Bon MA; Jansen Steur EN; de Vos RA; Vermes I
    Neurosci Lett; 1999 May; 266(2):149-51. PubMed ID: 10353349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-gene and gene-environment interaction on the risk of Parkinson's disease.
    Singh NK; Banerjee BD; Bala K; Chhillar M; Chhillar N
    Curr Aging Sci; 2014; 7(2):101-9. PubMed ID: 25101650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families.
    Lucotte G; Turpin JC; Gérard N; Panserat S; Krishnamoorthy R
    Am J Med Genet; 1996 Jul; 67(4):361-5. PubMed ID: 8837703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic predisposition to Parkinson's disease: CYP2D6 and HFE in the Faroe Islands.
    Halling J; Petersen MS; Grandjean P; Weihe P; Brosen K
    Pharmacogenet Genomics; 2008 Mar; 18(3):209-12. PubMed ID: 18300942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the oxidative polymorphism and early onset of Parkinson's disease.
    Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F
    Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease.
    Tsuneoka Y; Matsuo Y; Ichikawa Y; Watanabe Y
    Metabolism; 1998 Jan; 47(1):94-6. PubMed ID: 9440484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphism of CYP2D6 in the Japanese population.
    Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
    Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 allelic frequencies in young-onset Parkinson's disease.
    Sandy MS; Armstrong M; Tanner CM; Daly AK; Di Monte DA; Langston JW; Idle JR
    Neurology; 1996 Jul; 47(1):225-30. PubMed ID: 8710083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease.
    Singh M; Khanna VK; Shukla R; Parmar D
    Dis Markers; 2010; 28(2):87-93. PubMed ID: 20364044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6 phenotypes and Parkinson's disease risk: a meta-analysis.
    Lu Y; Peng Q; Zeng Z; Wang J; Deng Y; Xie L; Mo C; Zeng J; Qin X; Li S
    J Neurol Sci; 2014 Jan; 336(1-2):161-8. PubMed ID: 24211060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism and Parkinson's disease in Taiwan: study of debrisoquine 4-hydroxylase (CYP2D6).
    Lo HS; Chen CH; Hogan EL; Kao KP; Wang V; Yan SH
    J Neurol Sci; 1998 Jun; 158(1):38-42. PubMed ID: 9667775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.
    Ur Rasheed MS; Mishra AK; Singh MP
    Neurochem Res; 2017 Dec; 42(12):3353-3361. PubMed ID: 28871472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease.
    Pang CP; Zhang J; Woo J; Chan D; Law LK; Tong SF; Kwok T; Kay R
    Mov Disord; 1998 May; 13(3):529-32. PubMed ID: 9613747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia.
    Gołab-Janowska M; Honczarenko K; Gawrońska-Szklarz B; Potemkowski A
    Neurol Neurochir Pol; 2007; 41(2):113-21. PubMed ID: 17530572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study.
    Taylor CA; Saint-Hilaire MH; Cupples LA; Thomas CA; Burchard AE; Feldman RG; Myers RH
    Am J Med Genet; 1999 Dec; 88(6):742-9. PubMed ID: 10581500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.